0000898432-20-000826.txt : 20201023 0000898432-20-000826.hdr.sgml : 20201023 20201023143815 ACCESSION NUMBER: 0000898432-20-000826 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201016 FILED AS OF DATE: 20201023 DATE AS OF CHANGE: 20201023 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alaska Permanent Fund Corp CENTRAL INDEX KEY: 0001582681 STATE OF INCORPORATION: AK FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 201257328 BUSINESS ADDRESS: STREET 1: 801 WEST 10TH STREET STREET 2: SUITE 302 CITY: JUNEAU STATE: AK ZIP: 99801 BUSINESS PHONE: 907-796-1500 MAIL ADDRESS: STREET 1: 801 WEST 10TH STREET STREET 2: SUITE 302 CITY: JUNEAU STATE: AK ZIP: 99801 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: C/O ARCH VENTURE PARTNERS STREET 2: 999 THIRD AVENUE, SUITE 3400 CITY: SEATTLE STATE: WA ZIP: 98104 BUSINESS PHONE: 857-400-4222 MAIL ADDRESS: STREET 1: C/O ARCH VENTURE PARTNERS STREET 2: 999 THIRD AVENUE, SUITE 3400 CITY: SEATTLE STATE: WA ZIP: 98104 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 4 1 form4.xml X0306 4 2020-10-16 0001659352 Codiak BioSciences, Inc. CDAK 0001582681 Alaska Permanent Fund Corp 801 WEST 10TH STREET SUITE 302 JUNEAU AK 99801 true Common Stock 2020-10-16 4 C 0 2616093 A 4512895 I See Footnote Common Stock 2020-10-16 4 C 0 467076 A 4512895 I See Footnote Common Stock 2020-10-16 4 C 0 747321 A 4512895 I See Footnote Common Stock 2020-10-16 4 C 0 191721 A 4512895 I See Footnote Common Stock 2020-10-16 4 C 0 191721 A 4512895 I See Footnote Common Stock 2020-10-16 4 P 0 235000 15 A 4512895 I See Footnote Series A redeemable convertible preferred stock 2020-10-16 4 C 0 20450000 0 D Common Stock 2616093 0 I See Footnotes Series B redeemable convertible preferred stock 2020-10-16 4 C 0 3333333 0 D Common Stock 467076 0 I See Footnote Series B redeemable convertible preferred stock 2020-10-16 4 C 0 5333333 0 D Common Stock 747321 0 I See Footnotes Series C redeemable convertible preferred stock 2020-10-16 4 C 0 1320097 0 D Common Stock 191721 0 I See Footnote Series C redeemable convertible preferred stock 2020-10-16 4 C 0 1320097 0 D Common Stock 191721 0 I See Footnotes Upon closing of the issuer's initial public offering, the Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock and Series C redeemable convertible preferred stock converted automatically into Common Stock without payment of further consideration. There was no expiration date for any of the series of preferred stock. The shares are held by ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in each of ARCH Venture Fund VIII, L.P. and ARCH Venture Fund VIII Overage, L.P.. The Reporting Person disclaims beneficial ownership of the securities, except to the extent of its pecuniary interest therein and the inclusion of the securities in this report shall not be deemed an admission of beneficial ownership for purposes of Section 16 or any other purpose. The shares are held by Yukon Investors, LLC. The Reporting Person holds an interest in Yukon Investors, LLC. The shares are held by ARCH Venture Fund VIII Overage, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII Overage, L.P.. The shares are held by ARCH Venture Fund VIII, L.P.. The Reporting Person holds an indirect interest in ARCH Venture Fund VIII, L.P.. Each share of Series A Preferred Stock converted automatically into Common Stock on a 1-for-7.8170 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. Each share of Series B Preferred Stock converted automatically into Common Stock on a 1-for-7.1366 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series B Preferred Stock was convertible based on a 1-for-7.1295 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. Each share of Series C Preferred Stock converted automatically into Common Stock on a 1-for-6.8855 basis into the aggregate number of shares of Common Stock shown in Column 7 without payment or further consideration upon closing of the Issuer's initial public offering on October 16, 2020. The reporting person previously reported shares of common stock into which the Series C Preferred Stock was convertible based on a 1-for-6.8758 conversion ratio estimated at pricing of the Issuer's initial public offering, which reflected a fixed conversion price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. price plus an estimated adjustment based on the issuance of shares in the Issuer's initial public offering. The Reporting Person is the Alaska Permanent Fund Corporation, acting for and on behalf of the funds which the Alaska Permanent Fund Corporation is designated by Alaska Statutes 37.13 to manage and invest. /s/ Angela Rodell 2020-10-21